Denosumab is indicated for treating osteoporosis in postmenopausal women, preventing skeletal-related complications in cancer ...

Treatment with denosumab vs oral bisphosphonates was associated with increased risks for MACE and hypocalcemia in dialysis-dependent patients with osteoporosis.

UK headquartered Hikma Pharmaceuticals, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc, have announced ...

Please provide your email address to receive an email when new articles are posted on . Denosumab is associated with a greater increase in lumbar spine bone mineral density at 12 months compared with ...

Please provide your email address to receive an email when new articles are posted on . “Although we observed an increasing number of osteonecrosis of the jaw cases in our daily practice during the ...

The study of postmenopausal women in Iran found the efficacy of the biosimilar was noninferior to the reference product and the safety was comparable after 18 months. As the global population ...

Patients with rheumatic diseases who are treated with denosumab (Prolia®, Xgeva®) either alone, or in combination with either biologic or non-biologic disease-modifying antirheumatic drugs (DMARDs), ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window AUSTIN, Texas -- ...

Compared with oral bisphosphonates, denosumab reduced fracture risk among treatment-experienced postmenopausal women with osteoporosis. Treatment with denosumab vs oral bisphosphonates is associated ...

Zoledronic acid is a potent bisphosphonate used as the standard therapy for the prevention of skeletal-related events in patients with solid tumors metastatic to bone. Three phase III studies have ...

Results of a large phase III randomized controlled trial—recently published online in the Lancet—have shown that denosumab can delay the onset of bone metastasis in patients with castration-resistant ...